Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
NTLA Intellia Therapeutics
43.850+0.620+1.43%
Close
02/06 16:00 ET
43.8500.0000.00%
Post Mkt Price 02/06 16:07 ET
High
44.240
Open
42.930
Turnover
32.54M
Low
42.410
Pre Close
43.230
Volume
745.78K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's Is How to Trade
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Russell Investments Group Ltd.
Russell Investments Group Ltd. cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 27.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm
Intellia Therapeutics (NASDAQ:NTLA) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of Intellia Therapeutics (NASDAQ:NTLA – Get Rating) in a research note issued to investors on Tuesday morning, The Fly reports. The firm issued an overwei
Editas, Beam Win Bullish Views as Cantor Launches Gene Editing Coverage
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15.The analyst says that following the recent pipeline reprioritization and p
Intellia Therapeutics Initiated at Overweight by Cantor Fitzgerald
Intellia Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics With Overweight Rating, Announces Price Target of $67
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $67.
Intellia Therapeutics Initiated With an Overweight at Cantor Fitzgerald
Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 34.6% in the third quarter, according to the company in its most recent 13F filing
Cathie Wood's ARK Investment Bought 195K Shares of Intellia Therapeutics Today
Company Overview
More
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
CEO： Mr. John M. Leonard, M.D.
Market： NASDAQ
Listing Date： 05/06/2016
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet